13 October 2022 - Telix Pharmaceuticals announces that Health Canada has approved Illuccix [kit for the preparation of gallium (Ga 68) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localising tumour tissue in recurrent prostate cancer.

Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the positron emission tomography of prostate specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

• with suspected metastasis who are suitable for initial definitive therapy
• with suspected recurrence with elevated serum prostate specific antigen (PSA) level

Read Telix Pharmaceuticals press release